You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
Name4-Methoxyamphetamine
Accession NumberDB01472  (EXPT03303)
TypeSmall Molecule
GroupsExperimental, Illicit
DescriptionNot Available
Structure
Thumb
Synonyms
(2RS)-1-(4-methoxyphenyl)propan-2-amine
4-methoxyamfetamine
D,L-p-methoxyamphetamine
Formoterol fumarate related compound G
P-methoxyamfetamine
P-methoxyamphetamine
Paramethoxyamphetamine
External Identifiers
  • J213.549C
  • J434.573H
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIOVB8F8P39Q
CAS number64-13-1
WeightAverage: 165.2322
Monoisotopic: 165.115364107
Chemical FormulaC10H15NO
InChI KeyInChIKey=NEGYEDYHPHMHGK-UHFFFAOYSA-N
InChI
InChI=1S/C10H15NO/c1-8(11)7-9-3-5-10(12-2)6-4-9/h3-6,8H,7,11H2,1-2H3
IUPAC Name
1-(4-methoxyphenyl)propan-2-amine
SMILES
COC1=CC=C(CC(C)N)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenethylamines
Direct ParentAmphetamines and derivatives
Alternative Parents
Substituents
  • Amphetamine or derivatives
  • Phenylpropane
  • Methoxybenzene
  • Phenol ether
  • Anisole
  • Aralkylamine
  • Alkyl aryl ether
  • Ether
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Primary aliphatic amine
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationNot Available
PharmacodynamicsNot Available
Mechanism of action4-Methoxyamphetamine is a seratogenic drug of the amphetamine class. The drug acts as a potent and selective serotonin releasing agent. It binds to alpha receptors to mediate these effects.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9971
Blood Brain Barrier+0.9283
Caco-2 permeable+0.7646
P-glycoprotein substrateNon-substrate0.688
P-glycoprotein inhibitor INon-inhibitor0.9424
P-glycoprotein inhibitor IINon-inhibitor0.9812
Renal organic cation transporterNon-inhibitor0.7678
CYP450 2C9 substrateNon-substrate0.8422
CYP450 2D6 substrateSubstrate0.8336
CYP450 3A4 substrateNon-substrate0.6008
CYP450 1A2 substrateInhibitor0.6567
CYP450 2C9 inhibitorNon-inhibitor0.9747
CYP450 2D6 inhibitorInhibitor0.8492
CYP450 2C19 inhibitorNon-inhibitor0.6537
CYP450 3A4 inhibitorNon-inhibitor0.9431
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8424
Ames testNon AMES toxic0.6201
CarcinogenicityNon-carcinogens0.8044
BiodegradationNot ready biodegradable0.875
Rat acute toxicity2.8848 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8836
hERG inhibition (predictor II)Non-inhibitor0.8576
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.928 mg/mLALOGPS
logP1.74ALOGPS
logP1.65ChemAxon
logS-2.2ALOGPS
pKa (Strongest Basic)10.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area35.25 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity50.17 m3·mol-1ChemAxon
Polarizability19.29 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (8.19 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Abiraterone.
Acebutolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Acebutolol.
Alprenolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Alprenolol.
AmineptineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Amineptine.
AmiodaroneThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Amiodarone.
AmitriptylineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Amitriptyline.
Arotinolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.
ArtemetherThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Artemether.
Atenolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Atenolol.
AtomoxetineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Atomoxetine.
Befunolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Befunolol.
Betaxolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Betaxolol.
BetaxololThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Betaxolol.
Bevantolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bevantolol.
Bisoprolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bisoprolol.
Bopindolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bopindolol.
Bufuralol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bufuralol.
Bupranolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Bupranolol.
BupropionThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Bupropion.
Carteolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Carteolol.
Carvedilol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Carvedilol.
CelecoxibThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Celecoxib.
Celiprolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Celiprolol.
ChloroquineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Chloroquine.
ChlorpromazineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Chlorpromazine.
CholecalciferolThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Cholecalciferol.
CimetidineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Cinacalcet.
CitalopramThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Citalopram.
ClemastineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Clemastine.
ClobazamThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Clobazam.
ClomipramineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Clomipramine.
ClotrimazoleThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Clotrimazole.
ClozapineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Clozapine.
CobicistatThe serum concentration of 4-Methoxyamphetamine can be increased when it is combined with Cobicistat.
CocaineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Cocaine.
CyclobenzaprineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Cyclobenzaprine.
DarifenacinThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of 4-Methoxyamphetamine can be increased when it is combined with Darunavir.
DelavirdineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Delavirdine.
DesipramineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Desipramine.
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of 4-Methoxyamphetamine.
DiphenhydramineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Diphenhydramine.
DosulepinThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Dosulepin.
DoxepinThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Doxepin.
DronedaroneThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Dronedarone.
DuloxetineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Duloxetine.
EliglustatThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Eliglustat.
EsmirtazapineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Esmirtazapine.
Esmolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Esmolol.
FluoxetineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Fluoxetine.
FluvoxamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Fluvoxamine.
HaloperidolThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Haloperidol.
ImipramineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Imipramine.
Indenolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Indenolol.
IndinavirThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Indinavir.
IsoniazidThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Isoniazid.
KetoconazoleThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ketoconazole.
Labetalol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Labetalol.
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of 4-Methoxyamphetamine.
LopinavirThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Lorcaserin.
LumefantrineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Lumefantrine.
MethadoneThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Methadone.
MethotrimeprazineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Methotrimeprazine.
Metoprolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.
MetoprololThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Metoprolol.
MianserinThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Mianserin.
MilnacipranMilnacipran may decrease the antihypertensive activities of 4-Methoxyamphetamine.
MirabegronThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Mirabegron.
MirtazapineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Mirtazapine.
Nadolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Nadolol.
NevirapineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Nevirapine.
NicardipineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Nicardipine.
NilotinibThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Nilotinib.
NortriptylineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Nortriptyline.
Oxprenolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Oxprenolol.
PanobinostatThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Panobinostat.
ParoxetineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of 4-Methoxyamphetamine can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Penbutolol.
Pindolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Pindolol.
Practolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Practolol.
PromazineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Promazine.
Propranolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Propranolol.
ProtriptylineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Protriptyline.
QuinidineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Quinidine.
QuinineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Quinine.
RanolazineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ranolazine.
RitonavirThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ritonavir.
RolapitantThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Rolapitant.
RopiniroleThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ropinirole.
SertralineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Sertraline.
Sotalol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Sotalol.
StiripentolThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Stiripentol.
TerbinafineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Terbinafine.
ThioridazineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Thioridazine.
TianeptineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Tianeptine.
TiclopidineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ticlopidine.
Timolol4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Timolol.
TipranavirThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Tipranavir.
TranylcypromineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Tranylcypromine.
TrimipramineThe therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Trimipramine.
VenlafaxineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Venlafaxine.
ZiprasidoneThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Daws LC, Irvine RJ, Callaghan PD, Toop NP, White JM, Bochner F: Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. [PubMed:11041537 ]
  2. Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE: Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther. 2002 Mar;300(3):1093-100. [PubMed:11861820 ]
  3. Fitzgerald JL, Reid JJ: Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol. 1990 Nov 27;191(2):217-20. [PubMed:1982265 ]
  4. Fleckenstein AE, Volz TJ, Riddle EL, Gibb JW, Hanson GR: New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol. 2007;47:681-98. [PubMed:17209801 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Daws LC, Irvine RJ, Callaghan PD, Toop NP, White JM, Bochner F: Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat. Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):955-77. [PubMed:11041537 ]
  2. Shankaran M, Yamamoto BK, Gudelsky GA: Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine. Eur J Pharmacol. 1999 Dec 3;385(2-3):103-10. [PubMed:10607865 ]
  3. Whitworth TL, Herndon LC, Quick MW: Psychostimulants differentially regulate serotonin transporter expression in thalamocortical neurons. J Neurosci. 2002 Jan 1;22(1):RC192. [PubMed:11756522 ]
  4. Szabo Z, McCann UD, Wilson AA, Scheffel U, Owonikoko T, Mathews WB, Ravert HT, Hilton J, Dannals RF, Ricaurte GA: Comparison of (+)-(11)C-McN5652 and (11)C-DASB as serotonin transporter radioligands under various experimental conditions. J Nucl Med. 2002 May;43(5):678-92. [PubMed:11994534 ]
  5. Boot BP, Mechan AO, McCann UD, Ricaurte GA: MDMA- and p-chlorophenylalanine-induced reduction in 5-HT concentrations: effects on serotonin transporter densities. Eur J Pharmacol. 2002 Oct 25;453(2-3):239-44. [PubMed:12398910 ]
  6. Saldana SN, Barker EL: Temperature and 3,4-methylenedioxymethamphetamine alter human serotonin transporter-mediated dopamine uptake. Neurosci Lett. 2004 Jan 16;354(3):209-12. [PubMed:14700733 ]
  7. Bogen IL, Haug KH, Myhre O, Fonnum F: Short- and long-term effects of MDMA ("ecstasy") on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem Int. 2003 Sep-Oct;43(4-5):393-400. [PubMed:12742084 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Involved in the ATP-dependent vesicular transport of biogenic amine neurotransmitters. Pumps cytosolic monoamines including dopamine, norepinephrine, serotonin, and histamine into synaptic vesicles. Requisite for vesicular amine storage prior to secretion via exocytosis.
Gene Name:
SLC18A2
Uniprot ID:
Q05940
Molecular Weight:
55712.075 Da
References
  1. Biezonski DK, Meyer JS: Effects of 3,4-methylenedioxymethamphetamine (MDMA) on serotonin transporter and vesicular monoamine transporter 2 protein and gene expression in rats: implications for MDMA neurotoxicity. J Neurochem. 2010 Feb;112(4):951-62. doi: 10.1111/j.1471-4159.2009.06515.x. Epub 2009 Nov 30. [PubMed:20002520 ]
  2. Hansen JP, Riddle EL, Sandoval V, Brown JM, Gibb JW, Hanson GR, Fleckenstein AE: Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity. J Pharmacol Exp Ther. 2002 Mar;300(3):1093-100. [PubMed:11861820 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Thioesterase binding
Specific Function:
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazoline > clonidine > epinephrine > norepinephrine > phenylephrine > dopamine > p-synephrine > p-tyramine > serotonin = p-octopamine. For antagonists, the rank order is yohimbine > phentolamine = mianser...
Gene Name:
ADRA2A
Uniprot ID:
P08913
Molecular Weight:
48956.275 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Green AL, El Hait MA: p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. J Pharm Pharmacol. 1980 Apr;32(4):262-6. [PubMed:6103055 ]
  2. Ask AL, Fagervall I, Ross SB: Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1983 Sep;324(2):79-87. [PubMed:6646243 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Green AL, El Hait MA: p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo. J Pharm Pharmacol. 1980 Apr;32(4):262-6. [PubMed:6103055 ]
  2. Ask AL, Fagervall I, Ross SB: Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1983 Sep;324(2):79-87. [PubMed:6646243 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Wu D, Otton SV, Inaba T, Kalow W, Sellers EM: Interactions of amphetamine analogs with human liver CYP2D6. Biochem Pharmacol. 1997 Jun 1;53(11):1605-12. [PubMed:9264312 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23